» Articles » PMID: 17803912

Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 2007 Sep 7
PMID 17803912
Citations 503
Authors
Affiliations
Soon will be listed here.
Abstract

TLR4 and MD-2 form a heterodimer that recognizes LPS (lipopolysaccharide) from Gram-negative bacteria. Eritoran is an analog of LPS that antagonizes its activity by binding to the TLR4-MD-2 complex. We determined the structure of the full-length ectodomain of the mouse TLR4 and MD-2 complex. We also produced a series of hybrids of human TLR4 and hagfish VLR and determined their structures with and without bound MD-2 and Eritoran. TLR4 is an atypical member of the LRR family and is composed of N-terminal, central, and C-terminal domains. The beta sheet of the central domain shows unusually small radii and large twist angles. MD-2 binds to the concave surface of the N-terminal and central domains. The interaction with Eritoran is mediated by a hydrophobic internal pocket in MD-2. Based on structural analysis and mutagenesis experiments on MD-2 and TLR4, we propose a model of TLR4-MD-2 dimerization induced by LPS.

Citing Articles

The Role of TLRs in Obesity and Its Related Metabolic Disorders.

Campos-Bayardo T, Roman-Rojas D, Garcia-Sanchez A, Cardona-Munoz E, Sanchez-Lozano D, Totsuka-Sutto S Int J Mol Sci. 2025; 26(5).

PMID: 40076851 PMC: 11900219. DOI: 10.3390/ijms26052229.


The amelioration effect of sesamoside on inflammatory response in septic shock.

Song D, Zhao X, Zhang Y, Wang M, Tang H, Fang J BMC Immunol. 2025; 26(1):15.

PMID: 40050706 PMC: 11884088. DOI: 10.1186/s12865-025-00695-7.


Aberrant anabolism hinders constructive metabolism of chondrocytes by pharmacotherapy in osteoarthritis.

Largo R, Mediero A, Villa-Gomez C, Bermejo-Alvarez I, Herrero-Beaumont G Bone Joint Res. 2025; 14(3):199-207.

PMID: 40042132 PMC: 11881514. DOI: 10.1302/2046-3758.143.BJR-2024-0241.R1.


Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection.

Shirey K, Romerio A, Shaik M, Leake D, Palmer C, Skupinska N Innate Immun. 2025; 31:17534259241313201.

PMID: 40033742 PMC: 11877469. DOI: 10.1177/17534259241313201.


De novo design of protein minibinder agonists of TLR3.

Adams C, Kim H, Burtner A, Lee D, Dobbins C, Criswell C Nat Commun. 2025; 16(1):1234.

PMID: 39890776 PMC: 11785957. DOI: 10.1038/s41467-025-56369-w.